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Abstract: Widespread screening with prostate-specific antigen (PSA) has led to a significant increase in the detection of early stage, clinically localized prostate cancer (CaP). Various treatment options for localized CaP are discussed in this review article including active
surveillance, radical prostatectomy, radiation therapy, and cyrotherapy. The paucity of high-level
evidence adds a considerable amount of controversy when choosing the “optimal” intervention,
for both the treating physician and the patient. The long time course of CaP intervention outcomes,
combined with continuing modifications in treatments, further complicate the matter. Lacking
randomized trials that compare treatment options, this review article attempts to summarize
the different treatment options and associated side-effects, including effects on health-related
quality of life, from current published literature.
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One of the major challenges in caring for men with newly diagnosed prostate cancer
(CaP) is deciding between the many treatment options available. Often, a patient with
newly diagnosed localized CaP seeks the “right” answer from his treating physicians.
In fact, short of encouraging participation in clinical trials, it is difficult to define
the “optimal” way to treat localized CaP. Currently, the treatment of localized CaP
remains controversial. This controversy is highlighted by a recent specialist survey on
the “optimal” treatment of a hypothetical patient with localized CaP: approximately
29% favored expectant management, 33% favored radiotherapy and 39% chose radical
prostatectomy.1 The lack of consensus amongst experts underscores how important
it is for men diagnosed with CaP to make an informed treatment decision through an
objective discussion of the risks and benefits of each approach. In planning a treatment,
the burden typically falls upon the primary diagnosing physician, most commonly
the urologist, to discuss with the patient both the choice of intervention and also the
concerns of quality of life and longevity. Each treatment often carries unique potential
for side effects, variable long term cancer control data. The long time course of CaP
intervention outcomes combined with continuing modifications in treatments further
complicate the matter.
This article will discuss surgical and nonsurgical options available for the treatment
of newly diagnosed localized CaP and will highlight some of the advances in each
area. For patients with low-volume and low-grade cancer, characteristics typically
associated with minimal risk of cancer progression, a considerable controversy exists
regarding the optimal treatment, including whether to treat at all. Finding the right
Clinical Interventions in Aging 2010:5 187–197
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approach for treating high risk CaP is also difficult. However,
while monotherapy with radical prostatectomy or radiation
may be adequate for some men, there are randomized trials
suggesting the need for a multi-modal approach to a more
aggressive high risk cancer.

Risk stratification
D’Amico and colleagues developed the concept of risk
stratification, allowing the classification of men into low-,
intermediate-, and high-risk pretreatment groups using
a combination of clinical data: prostate-specific antigen
(PSA), Gleason sum, and clinical stage (Table 1).2 The
classification was originally developed to estimate the risk
of biochemical recurrence following treatment for localized
CaP and has become an important component in treatment
recommendations. Other methods such as the Partin tables
or Kattan nomograms may help guide therapy as they
suggest the probability of organ confined disease or if the
cancer has spread outside the prostate.3 In the current era of
multimodality therapy, this data may help guide treatment
choices as well as create realistic expectations on the
probability that a single treatment would be successful or if
a combined approach is likely to be necessary.
Additional patient specific data may aid in determining
the aggressiveness of CaP and guide recommendations
towards the best treatment option. For example, a rise of
PSA . 2.0 ng/mL/year before radical prostatectomy was a
predictor for CaP mortality with a 15% CaP mortality rate
at 7 years. No patients with a PSA rise of ,2.0 ng/mL/year
before surgery died from CaP. This rise of .2.0 ng/mL/year
identifies a group of patients with aggressive and potentially
life threatening CaP.4 A PSA density .0.15 ng/mL/cm3
predicted those more likely to receive active treatment after
active surveillance (AS).5 These studies suggest that clinical
data including PSA kinetics may identify patients at elevated
risk of disease progression and have a potential role in patient
counseling in favor or against specific therapy.

Active surveillance and watchful waiting
Growing in popularity are “treatment” approaches for
localized, asymptomatic CaP that do not involve an active
intervention: active surveillance and watchful waiting (WW).
Table 1 D’Amico risk stratification of prostate cancer2
Low risk
Intermediate risk
High risk
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PSA ng/mL

Gleason sum

Clinical stage

#10
10–20
$20

#6
7
8–10

#T2a
T2b
$T2c
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While similar, there are distinct differences. Watchful waiting
is now considered the intent to treat only if, or when, metastases or symptomatic progression appears. This is usually
limited to asymptomatic men with limited life expectancy
who often have high grade tumors. Contemporary AS protocols aim to treat, with curative intent, those prostate cancers
that develop more aggressive features during a period of
surveillance and while the CaP is still amenable to definitive
therapy such as surgery or radiotherapy. While there is no
uniform consensus at present, AS generally involves periodic
follow up examinations, PSA testing and repeat biopsy.
Advocates of AS argue that CaP is over treated in the
United States. There is a glaring discrepancy between the
number of patients diagnosed with CaP and the number of men
that will die from this disease. There is a 16% lifetime risk of
being diagnosed with CaP but only a 3% lifetime risk of dying
from it.6 Autopsy data shows that despite the presence of CaP
in one-third of men over age 60 and up to 50% of men over
70, men in the United States are more likely to die of other
comorbid conditions.7 Knowledge of the natural history of
low-risk CaP has also improved. Parker, et al estimated that
the 15-year CaP specific mortality for conservative management of screen detected CaP was 0%–2% if the Gleason score
were ,7.8 Data from the recently completed European Randomized Study of Screening for Prostate Cancer, estimated
the lead time associated with PSA screening to be 10.3 years
and the over diagnosis rate to be 54%.9 These studies highlight
the need to identify more definitive factors to distinguish
insignificant disease from that which will result in disease
specific morbidity and mortality.
One of the challenges of an AS protocol is the concern
of under sampling and inadequate mapping of the volume
of cancer present. An AS study from MD Anderson Cancer
Center demonstrated very low upstaging at the time of
prostatectomy and that all specimens had organ confined
tumor. The transition zone was involved in 29% of unifocal
and 71% of multifocal tumors.10 Therefore when instituting
an AS program, a repeat biopsy is usually recommended.
Despite these findings, van den Bergh et al have shown that
delayed intervention within 2 years does not have worse
pathologic features compared to patients who undergo
immediate radical prostatectomy.11 Only a small percentage
of patients on AS will show signs of disease progression,
with an estimated risk of metastasis of ,1% at 2 to 8 years
while on surveillance.11,12,13 Also, patients with low-risk
features (PSA , 10 ng/mL, clinical stage T1–T2a, and biopsy
Gleason sum 6 or less) who select AS have an estimated
disease-specific mortality of 1% at 8 years.14 (See Table 2)
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Table 2 Preliminary outcomes of active surveillance
Author

Eligibility criteria

Criteria for intervention

Median age

Median
follow-up

DSS

Dall-Era, et al13

T1–1, GS # 6,
PSA ,10 ng/mL
% positive cores ,33%
T1c–T2a, GS # 6,
PSA # 10 ng/mL

GS $ 7, increase
PSA or tumor volume

63 yrs

43 mos

100%

PSADT # 3yrs,
PSA . 10 ng/mL,
PSAV 2 ng/mL/yr

70 yrs

72 mos

99%

Klotz14

Abbreviations: PSA, prostate specific antigen; GS, gleason score; PSADT, PSA doubling time; PSAV, PSA velocity; DSS, disease specific survival.

If a patient progresses on an AS protocol, early intervention
can be offered. As noted, delayed intervention does not appear
to significantly compromise successful outcomes compared to
immediate intervention. Several other studies have also demonstrated that low-risk patients who delayed prostatectomy for
medians of 6 and 22 months did not experience more adverse
pathologic outcomes nor a compromised curability.15,16
Patients need to be counseled that AS, as the name implies,
is an active approach to following cancer and to reassure
them that, if their tumor shows any sign of biochemical or
pathologic progression during follow-up, intervention can be
undertaken safely at that time with minimal added risk.
AS allows close follow-up of disease and intervention
with curative intent triggered by early signs of disease

p rogression. An accepted definition of suitable candidates
for AS has been offered by Epstein and associates. Based on
the Hopkins radical prostatectomy experience, preoperative
parameters were assessed to predict which patients were
likely to harbor cancers with low risk, favorable features.
A PSA density (PSAD) , 0.15 ng/mL, clinical stage T2a
or less, and no biopsy Gleason grade 4 or 5 led to a 73%
predictive accuracy for favorable disease.17 The AS strategy
is appropriate for patients who have a life expectancy of
less than 10 years and for healthy men 65 years of age or
older who have low-volume, low-grade CaP as noted by
Epstein.18 This approach avoids the potential complications of
definitive therapy. From a quality of life standpoint, possible
adverse effects of AS include increased anxiety and patient

Eligibility
• PSA <10
• Gleason §6
• cT1c-cT2a

Active
surveillance
key points
Follow-up

Intervention

• PSA, DRE q3 mos
x 2yrs, then q6 mos

• Grade increase to
Gleason 7

• Biopsy at 1yr, and
then q3 to 5yrs

• PSA doubling time
<3yrs

Figure 1 Summary of active surveillance.
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c ompliance with repeated prostate biopsies. Clinical progression and loss of the opportunity for definitive “cure”, while
rare in properly selected men, remains a concern. Patient
eligibility into active surveillance, subsequent follow-up, and
when to intervene is summarized in Figure 1.

Radical prostatectomy
One very clear advantage of radical prostatectomy (RP)
over other treatment options is precise pathologic staging.
As noted, prostate needle biopsy is not entirely accurate,
and therefore non-surgical treatment decisions are often
made based on Partin or Kattan nomograms. At times, these
nomograms may under stage the extent of CaP. For example,
extracapsular extension (ECE) has been found in up to 15%
of patients with presumed low risk organ-confined disease.
In addition, roughly a third of the patients undergoing
prostatectomy will experience a significant upgrade of their
Gleason score (upstaging of pattern Gleason 3 to a diagnosis
of pattern Gleason 4 or 5).19 Following RP, a urologist has
clear pathologic data on determining whether the local cancer
has been removed, and reassure the patient of a 10-year
disease-free survival of well above 90%.20
From a quality of life concern, RP provides the added
benefit of an unambiguous interpretation of post-operative
PSA, so that a patient can often be reasonably assured that his
cancer was removed based on an “undetectable” PSA level
(standard PSA assay of ,0.2 ng/mL). If the patient’s disease
is upstaged to pathologic T3 or T4 disease after RP, the patient
can be counseled on the use of adjuvant radiation therapy in
a timely fashion, which has been shown to reduce the risk of
metastasis and improve overall survival.21,22 In addition, an
inability to achieve an undetectable PSA or a PSA recurrence
following RP (PSA . 0.2 ng/mL), allows for early therapy
in a salvage or an adjuvant fashion. Boorjian et al showed
that adjuvant radiotherapy was associated with significantly
improved 10-year biochemical recurrence-free survival,
local recurrence-free survival and a decreased need for late
hormone therapy.23 Also, in patients who received salvage
radiation, the risk of local recurrence was decreased and
systemic progression and hormonal therapy was delayed.
Once again, there is a paucity of clinical trials comparing
radical to other treatment modalities. The American College of
Surgeons Oncology Group attempted a trial that randomized
low risk men between brachytherapy and radical prostatectomy. Due to very poor accrual, the trial was never completed.24
One prospective randomized trial has shown a distinct survival
advantage of RP over watchful waiting. At 12 years, 12.5%
of the surgery group and 17.9% of the watchful waiting group
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had died of CaP, and at 12 years, 19.3% of men in the surgery
group and 26% of men in the watchful waiting group had been
diagnosed with distant metastases.25 A retrospective cohort
analysis compared oncologic cure rates for RP, external beam
radiation therapy (EBRT) and brachytherapy in low-risk CaP.
Follow-up of up to 8 years after therapy showed a significant
PSA failure-free survival advantage for RP over EBRT (88%
vs 78%). However, the study has been criticized, as the
EBRT patients received on average RT dose of 70 Gy, which
is currently considered a low dose, as dose escalation above
this level has shown to improve biochemical disease specific
survival.26 Regardless, long term outcomes after RP are strong
with RP considered by most to be the “gold standard” in the
treatment of localized CaP.
A recent multi-institutional study of prostate cancer
specific mortality (PCSM) after RP at 15 years was 12%.27
Results from this study helped establish a nomogram that
predicts that only 4% in the modern PSA era of contemporary
patients, had a predicted 15-year PCSM of greater than 5%.
The authors concluded that few patients will die from CaP
within 15 years of radical prostatectomy, even with adverse
clinical features.28
Excellent outcomes after RP have been reported in older
men as well. In patients .70 years of age, 10-year cancerspecific survival rates for low, intermediate and high risk
were 99.5%, 97.5% and 94%, respectively.28 Postoperative
complications in men aged 70–74 years were comparable
to the younger cohort of men aged 65–69 years. The rate of
complications was only slightly higher in patients 75 years and
older. Outcome of RP is related much more to the preoperative
comorbidity than to age alone.29 A life expectancy .10 years
is the most frequently used benchmark for prostatectomy as
definitive therapy for patients with localized CaP.30
With its introduction over a decade ago, laparoscopic radical
prostatectomy (LRP) challenged the standard retropubic and
perineal approaches. LRP has been criticized for its difficult
learning curve and its long operating times, allowing only limited
centers of excellence to perform this technically demanding
operation. Robotic-assisted technology has further allowed
the transition of the LRP into the robotically assisted radical
prostatectomy RARP.31 Now nine years after its approval by
the FDA, sixty-three percent of Tier I hospitals own a daVinci
surgical system, and the robotic approach accounted for 81% of
all prostate-removal procedures in the US last year.32
There are several potential advantages of the robotic
approach. RARP is associated with decreased blood loss,
and a shorter hospital stay. RARP also appears to afford
faster convalescence when compared to the RP, while still
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achieving similar oncologic outcomes.33 Although, long term
oncologic data is not available yet with RARP, there are
numerous series evaluating positive margin rate (PSM), an
independent predictive factor for biochemical recurrence. In a
review of a comparison of matched-pair analysis of open RP
versus RARP, no difference in the PSM rates between RARP
and open RP was noted, and the intermediate biochemical
progression-free survival was also not significantly different.34
By contrast with these results, in a cumulative analysis of six
comparative studies reporting data on margins, Ficarra et al
showed a statistically significant difference in favor of RARP
over open RP.20 A recent multicenter analysis published in
JAMA reviewed the outcomes of about 2,000 men treated
with minimally invasive surgical techniques from 2003 to
2007.35 They were compared with approximately 6,900 men
who had standard open radical prostatectomy. The minimally
invasive surgical group had shorter hospital stays and fewer
immediate surgical complications compared with open
surgery. However, 18 months post operatively, there was a
greater risk of incontinence and erectile dysfunction in comparison to the open surgery group. When adjusted for both
patient and tumor characteristics, men in both groups required
similar amounts of adjuvant therapy. Additional long term
studies will be necessary if the claims of improved outcomes
of minimally invasive surgery for CaP will be validated.
As more surgeons learn and perform RARP, it is likely that
further modifications will be made at improving outcomes.
Kaouk et al have described using laparo-endoscopic single-site
surgery (LESS) to perform RP. This technique is performed via
a single umbilical incision, with all instruments used through
the single site. This is illustrative of the recent shift in surgery
to more even more minimally invasive approaches.36
Lastly, a comment should be made concerning the major
shift in the management of node positive CaP at the time of
radical prostatectomy. Although the classic teaching is that
the procedure should be abandoned in the setting of lymph
node involvement, recent data including prospective clinical
trials and retrospective analysis suggests that this is no longer
considered proper management.37,38 Overall survival may
in fact be improved with the removal of both the prostate,
lymph nodes and the immediate use of hormonal therapy.38
Data from Messing et al also suggests that a subset of men
with positive nodes may have long term disease free survival
without additional hormonal therapy.37
In conclusion, in order to fully counsel a patient about which
surgical modality to choose with regards to complications, oncologic and functional outcomes, a large randomized controlled
trial comparing open vs laparoscopic vs robotic-assisted
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p rostatectomy are required but none are currently planned. One
factor that has been shown to improve both the cancer control
and functional results of radical prostatectomy is the experience
of the surgeon, regardless of the technique.39

Radiation therapy
The field of radiation oncology for the treatment of localized
CaP is constantly being reevaluated to optimize delivery
and optimize cancer control but also to minimize damage
to surrounding normal tissues. Development of better
cancer-targeting therapies in the form of three-dimensional
conformal radiation therapy (3DCRT) and intensity-modulated
radiotherapy (IMRT) and the use of image guided (IGRT)
techniques such as fiducial markers theoretically decrease
the side effects seen with EBRT.40 Similarly, during this
same time frame, other advances in the field have supported
the use of higher doses of radiation for organ-confined disease
and the use of androgen deprivation therapy (ADT) concurrent
with EBRT with higher risk tumors.
Data from retrospective analyses suggest that the noted
technical improvements translate into decreased rates of
local failure and distant metastases, as well as better overall
survival. An example of these findings is shown in an analysis
of 1,465 men treated in four randomized trials conducted by
the Radiation Therapy Oncology Group (RTOG). Radiation
doses .66 Gy were associated with a 29% lower relative
risk of death from CaP compared to lower doses.41 It is clear
that for the treatment of intermediate to high-risk CaP with
radiotherapy high doses are needed for high tumor control.
In randomized studies of low dose compared to high dose,
a better biochemical control, expressed as PSA-control, was
found in favor of the high-dose groups.42,43 Multiple trials have
demonstrated that doses of 78 to 80 Gy are needed to obtain
definitive therapy for CaP, which is a great increase from the
70 to 74 Gy that was previously the standard of care.43,44 As the
technology to deliver more accurate RT develops even higher
radiation doses are being considered. The RTOG 0126, a large
randomized dose escalation trial to look at doses in excess of
81 Gy, recently completed accrual.45 Given the fact that dose
escalation of RT has shown a survival benefit for men, there
is optimism that further dose escalation may benefit patients
with high-risk localized disease. Although it is feasible to
administer doses in excess of 81 Gy using these techniques,
whether doses above 78 Gy provide added benefit for men
with low-risk disease remains controversial.
The use of RT in combination with ADT for CaP patients is
clearly supported by multiple randomized trials.46,47 However, several questions remain unanswered, including the optimal sequenc-
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ing and duration of androgen deprivation. In the RTOG 8610,
471 men were randomly assigned to RT with or without Zoladex
plus flutamide. ADT was administered for 2 months before and
2 months during RT. At a median follow-up of 12.5 years, ADT
significantly decreased the rates of disease-specific mortality,
distant metastases, and biochemical failure (23% vs 36%, 35%
vs 47%, and 65% vs 80% with and without ADT, respectively)
while increasing the rate of disease-free survival (11% vs 3%).48
D’Amico et al reported a survival benefit with neoadjuvant
(NADT) of 6 months in patients with intermediate risk CaP.47 The
major endpoint of the study was overall survival and the time to
PSA . 1.0 ng/mL and an increase in the PSA by .0.2 ng/mL
on two consecutive occasions. Patients randomized to receive
NADT had a significantly improvement in overall survival, cause
specific survival and survival without salvage ADT. One drawback in these studies is that the dose of RT delivered would be
considered suboptimal by today’s standards, and therefore would
ADT provide benefit in current patients receiving higher radiation
doses? Therefore, some investigators have argued that if adequate
local doses are given ADT may not be required.49
Another area of advancement has been with the use of
prostate markers to allow for an accurate guide in delivering
RT. Our experience from the Kimmel Cancer Center has shown
that placement of gold fiducial markers can easily be placed in
an outpatient setting, more importantly, these markers allowed
accurate delivery of RT while limiting acute toxicity.40 Investigators at the University of California San Francisco (UCSF) have
shown that prostate markers provide an accurate guide such that
treatments can be delivered within 2 mm, without the risk of seed
migration.50 This progression has allowed the development in
the field of image guided radiotherapy (IGRT) and 4D CRT. The
“fourth dimension” in this setting refers to the impact of time
on the position and/or shape of the target volume allowing tight
margins that can be placed around the target tissues.
Monotherapy with radioactive seeds is preferably reserved
for patients with low-risk disease, many groups are combining
seed brachytherapy with EBRT for patients with intermediate
to high-risk disease. The goal of this approach is to aim at
higher tumor dose and better coverage of the target volume
because of presumed extension of cancer cells beyond the
prostate boundaries. The advantage of multi-modal RT is
also seen in high-dose-rate brachytherapy in conjunction with
IMRT over IMRT alone. The 3-year biochemical disease-free
survival rates in high-risk patients treated with IMRT alone
was 67% as opposed to 93% in the high dose rate (HDR)
brachytherapy and IMRT group.51 The same benefit has
also been shown in intermediate and high-risk patients who
received 3DCRT with a single HDR brachytherapy implant
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over 3DCRT. The 5- and 7-year biochemical control rates
for intermediate were 82.5% and 80.3%, respectively, for the
combined group and 81.3% and 71%, respectively, for 3DCRT
alone. In addition, there was minimal toxicity in patients with
unfavorable CaP who underwent combination therapy.52
Stereotactic body radiotherapy is being rapidly deployed
in the treatment of localized CaP. The prostate target is usually
localized in space using an external frame of reference
which can be related to the treatment machine. Stereotactic positioning can be precise and as a result, stereotactic
radiotherapy commonly employs higher doses per fraction
and fewer fractions (hypofractionation) than conventional
radiation. Stereotactic body radiotherapy typically consists
of a total course of therapy comprising five or fewer treatments. Many commercially available systems are currently
used that typically incorporate some type of sophisticated
image guidance and most also have patient immobilization
devices (eg, CyberKnife® Robotic Radiosurgery System,
Accuray, Inc., Sunnyvale, CA and many others). The utility
of hypofractionation in the treatment of CaP is not conclusive
and awaits the results of ongoing randomized trials to confirm any of the hypofractionation advantages over routinely
administered (normofractionated) radiotherapy.53
Proton beam, or charged-particle beam, radiotherapy for
CaP was first used at Massachusetts General Hospital in the
1970s, but recently has received increased attention in press
for the treatment of CaP. In theory, proton particles have better
depth penetration than traditional photon or electron beam
therapy and therefore, should deposit most of their energy
near the tumor site rather than at the skin level. In addition,
very little of the prescribed dose travels past the site of tumor,
whereas, photons continue to deposit the dose of radiation in
normal tissues beyond the tumor. This phenomenon is known
as Bragg peak, where the pattern of delivery is localized with
a sharp drop off past the projected site of delivery.54
In a phase II trial comparing the dosimetric characteristics
of protons and IMRT, Vargas et al showed a decrease of 59%
and 35% of the rectal and bladder dose, respectively.54 Proton
beam therapy is expected to deliver biologically equivalent
doses more precisely and with less radiation-induced
morbidity than conventional photon radiation therapy. It is
unclear whether the claimed high precision in dose delivery
is beneficial, let alone necessary, for the treatment of CaP
when compared to contemporary radiation techniques.

Cryotherapy
Cryotherapy has been used for surgical lesions since the 1850’s,
when it was first introduced by Dr James Arnot.55 The American
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Urologic Association (AUA) recognized cryotherapy first in
1996 for the treatment of CaP. Although, only recently, the AUA
has accepted cryosurgery as a primary modality in treatment
of localized CaP, published in Best Practice Statement on
Cryosurgery for the Treatment of Localized Prostate Cancer.56
Cryotherapy is currently indicated in low-risk patients as an
alternative to prostatectomy or radiotherapy, in higher-surgicalrisk patients as primary therapy, and in patients who have not
responded to radiation therapy as a salvage procedure.
Historically, cryosurgery was associated with relatively
high risks, such as urethral sloughing, rectal injury and urinary
fistulas. Major advances have occurred in the delivery of
cryotherapy in the past 15 years. A significant development
was the introduction of cryotherapy probes that use argon gas
rather than liquid nitrogen. Argon rapidly cools the probe tip to
-187°C (-304.6°F) and can be rapidly exchanged with helium
at 67°C (152.6°F) for an active thawing phase, producing a
faster response to operator input and significantly speeding
2-cycle treatment.57 Moreover, argon-based probes have a
much smaller diameter, thus permitting direct, sharp transperineal insertion, facilitating more conformal cryosurgery.
Gland volume is an important factor: larger prostates may
be more difficult to treat because of the difficulty in achieving a
uniformly cold temperature throughout the gland. Neoadjuvant
therapy for downsizing the gland may be considered in such
patients, although there are no published studies on this topic.
With the newer generation of cryoprobe needles, urethral
and rectal warming catheters, real-time temperature monitoring,
the rates of complications have been drastically improved.
In a review of current literature, the rates of incontinence,
urethral fistula, and urethral sloughing are reported to be
2%–7%, 0%–2%, and 2%–6%, respectively.58,59,60 Han et al
reported good outcomes in a series of 106 patients with
only 3% incontinence requiring pads, 5% urge incontinence
requiring no pads, 3.3% transient urinary retention, and 2.6%
rectal pain.59 This demonstrates the relatively low complication profile of cryotherapy. Short of any head to head trials,
in terms of being minimally invasive, the side-effect profile
of cryoablation is comparable to EBRT and brachytherapy.
Moreover, in a study by Hubosky et al at 18-month follow-up,
cryosurgery patients had better urinary function compared with
a series of brachytherapy patients, and this improvement was
still present at 24 months.58 Robinson et al presented quality
of life (QoL) outcomes from a single institution randomized
trial comparing EBRT with cryotherapy for localized CaP.
Cryoablation patients reported lower urinary function scores
(69.4 vs 90.7), similar bowel function, and lower sexual
function scores (7.2 vs 32.9). At 36 months EBRT men had
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slightly lower urinary function scores but no difference in
bowel function scores. The cryoablation patients had lower
sexual function scores at 36 months (16 vs 36.7).61
One major downside to cryosurgery is the high risk of
erectile dysfunction. This occurs primarily because the
effective “kill zone” to ensure adequate prostatic coverage
extends to the periprostatic tissue, which includes the
neurovascular bundle, necessary for erection. Hubosky
et al reported that only 20% of the entire cohort was able
return to baseline sexual function at 12-month followup. 58
This is similar to other published studies that report the
incidence of ED after total gland cryosurgery, to be nearly
90 percent of patients at 1 year of follow-up.59,60 Therefore,
patients for whom preservation of erectile function is a
high priority are probably less-than-ideal candidates.
One of the drawbacks of cryotherapy, similar to RT, is that
post intervention monitoring of recurrent disease or failure of
treatment can be difficult. Most commonly, similar to post RT
patients, PSA is followed but the definition of biochemical
failure is not universally defined. The two definitions, ASTRO
criteria and the Phoenix criteria, described in EBRT data are
implemented in the cryotherapy literature. Others have used
a strict PSA cutoff. However, the nadir PSA cutpoint that
should represent the absence of cancer remains uncertain.
Long-term retrospective data from Cohen et al reported
10-year biochemical Disease Free Survival (bDFS) of 56.01%
according ASTRO criteria and 62.36% using the Phoenix
criteria (nadir plus 2 ng/mL). When stratified by risk groups
(low, medium, and high), bDFS using the Phoenix criteria was
80.56%, 74.16%, and 45.54%, respectively.62
Jones et al recently published the largest series of patients
undergoing whole gland cryotherapy as primary treatment,
all of whom were included in the Cryo On-Line Database
(COLD) registry the largest cohort published regarding whole
gland cryotherapy for localized CaP. The median pretreatment PSA level was 6.8 ng/mL (mean, 9.6 ± 8.6 ng/mL), and
various Gleason scores were represented (median, 7). The
mean follow-up period was 24.4 ± 25.9 months. Applying the
Phoenix definition to the data from men accumulated in that
registry, 91 percent of men with low-risk, 78 percent of men
with intermediate-risk, and 62 percent of men with high-risk,
localized CaP experienced biochemical recurrence.63
The COLD registry is a multicenter collaboration,
was developed and incorporates data from four academic
medical centers and 34 community urologists, so that control of the generation of cryosystem used and treatment
protocols varied among different centers. This inherently
weakens the data as there is no standardization in deliver-
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ing the treatment modality. More importantly, 49.5% of
these men received hormone therapy prior to cryoablation,
perhaps giving a false undetectable PSA.63 Regardless,
published data from the COLD registry report 5-year bDFS
of 77.1% using the ASTRO criteria and 72.9% using the
Phoenix criteria. Using risk stratification, the 5-year bDFS
was 84.7%, 73.4%, and 75.3% (ASTRO) and 91.1%, 78.5%,

and 62.2% (Phoenix) for low-, medium-, and high-risk
groups, respectively.63
As discussed earlier, incidence of ED is high in patients
undergoing whole gland ablation. Although still in experimental
stages, focal cryoablation, or commonly coined term the “male
lumpectomy” of the prostate is developing as a potential option
for patients with unilateral, low-risk cancer. The goal behind

Table 3 Comparison of some prostate cancer treatment options for localized disease
Treatment

Benefits

Limitations

Active surveillance/watchful
waiting

• Avoids treatment of insignificant cancer
• Not risks of side effects from surgery
or radiation

Radical prostatectomy

• Accurate pathologic staging
• Allows PSA to be more reliable marker
of disease control
• Trials demonstrate reduction in prostate
cancer specific deaths
• Allows potential for nerve sparing procedure
• Long term outcome data available (for open
radical prostatectomy)
• Compared to radiation treatments, less issues
with urinary frequency or urgency, rectal and
bowel irritation
• Salvage possible with EBRT
• Avoids hospital stay and risk of surgery
• Outpatient, limited impact on daily living
• Long term cancer control reported
• Addition of hormonal therapy improved
cancer control for high risk
• Incontinence rare (1%–2%)
• Urinary retention less common than with
brachytherapy

• Potential “anxiety” from not treating a diagnosed cancer
• Regular rectal exams, PSA testing with periodic/multiple
biopsy to monitor
• Possibility that “window of curability” may be missed
• Surgical risks (infection, bleeding, reaction to anesthesia, etc)
• For laparoscopic/robotic technique: additional risk of
intrabdominal injury or pneumoperitoneum related
complications; limited long term outcome data at present
• Limited physical activity in recovery period (2–4 weeks)
• Post op complications of incontinence: 5%–20% (usually
stress); erectile dysfunction: up to 50% at 5 years (with nerve
preservation, may be improved by medical therapy); bladder
neck contractures 1%–3%; lymphocele with retropubic
approach; rare rectal injury

External beam radiation
therapy (EBRT)
(normofractionation)

Stereotactic body
radiotherapy
(hypofractionation)
Brachytherapy

• “Convenient” outpatient treatments
as short as five days

Proton beam therapy

• Ability to deliver dose to prostate
and avoid other structures

Cryotherapy

• One time treatment, often outpatient
• Can be repeated
• Allows for potential “focal” therapy
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• Minimal surgical risks, one time outpatient
surgical procedure
• Best for low risk prostate cancer
• Delivers higher dose to prostate target,
less to surrounding tissues
• Long term data available
• Low rate of incontinence (1%–2%)
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• No post-treatment staging information
• Daily treatments for 6–8 weeks
• Fatigue may occur when treatment ends
• Erectile dysfunction: up to 50% at 5 years
• Bowel/rectal problems: 5%–10% (urgency, pain, diarrhea, or
bleeding) but typically improve after treatment
• Bladder irritation: 5% (urinary frequency, urgency, discomfort)
• Salvage therapies limited or associated
with high complication rate
• Utility and side effect profile not well studied

• Not useful for intermediate or high risk cancer
• Very small and very large glands (,20 cc, .80 cc) challenging
• No final pathologic staging
• Less favorable option for men with intermediate- or high-risk
disease
• Not recommended for men with significant lower urinary
tract symptoms
• Urinary tract side effects (retention, urgency, frequency) more
common than with other therapies
• ED outcomes similar to EBRT
• Salvage therapies limited or associated with high complication
rate
• Most costly infrastructure of all treatments
• No trials to demonstrate superiority over current radiation
modalities
• Limited number of facilities
• No final pathology
• Side effect profiles can be difficult to manage, but improving
with newer techniques
• High rate of ED for whole gland therapy
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focal therapy is to allow effective tumor ablation while sparing
the neurovascular bundle. Onik et al reported their result of
forty-eight patients with a mean follow-up of 4.5 years, who
had focal cryoablation. Forty-five of 48 patients (94%) had
stable PSAs, using the ASTRO criteria, with no evidence for
cancer. Twenty-four patients who underwent routine biopsy
had no evidence of disease.64
Focal cryoablation may therefore have a potential role for
low-risk patients with unilateral disease on biopsy who are
desirous of preserving erectile function. A study by Ward et al
reviewed prostate specimens with unilateral positive prostate
biopsy to characterize the location, volume and grade of each
tumor focus, in determining if focal therapy templates could
eradicate tumor burden. Despite only 17% of patients having
a single focus of cancer, hemi-prostate treatment templates
that would have been used in focal therapy would have successfully treated all clinically significant prostate tumor foci
in 81% of patients. Most out-of-field cancers were clinically
insignificant tumors not identified by prostate biopsy (lowvolume, 0.5 mL; and low grade, Gleason score , or = 6).65
Contemporary results of focal cryotherapy demonstrate
high-potency rates of approximately 90%.64,66

Other treatment modalities
High intensity focused ultrasound (HIFU) is approved in the
EU and in Canada but is not commercially available in the US.
High dose rate radiation (HDR) employs temporary prostate
implantation that requires a short hospital stay. It is usually done
in combination with external beam radiation therapy. At present
data is limited on this approach and the number of facilities that
perform prostate cancer HDR in the US is limited.
Many elderly men with localized CaP receive only horm
onal therapy. However, the benefit of hormonal monotherapy
(LHRH analogue alone, LHRH in combination with antiandrogens or with antiandrogens alone) in localized cancer is
not clear and can be associated with severe toxicities in some
men.67 Treatment guidelines do not recommend its use as a
first-line therapy at earlier disease stages. Despite limited

evidence to date for the impact on clinical outcomes, the use
hormonal monotherapy therapy in patients with localized or
locally advanced CaP has increased in many countries, most
notably Japan.68 Hormonal therapy, either using LHRH analogues alone or in combination with antiandrogens is currently
controversial in localized CaP as a monotherapy and should
not be used routinely until additional data is available.

Conclusion
As illustrated in this paper, there are numerous treatment
options available for the management of localized CaP. At
the present time, there is no single correct or “best” option
for all men. The limited availability of head to head randomized trials makes picking the right treatment option more
difficult. The trend for patients seeking multidisciplinary
clinical consultations are often facilitated at cancer centers
with a commitment to these patient centric efforts.69
As noted by the AUA, various factors must be taken into
consideration when making a collective decision in the man
with clinically localized CaP.70 Consideration for enrolling
the patient in a randomized trial is always a top priority as we
move the care of our patients ahead. The comparisons of the
risks and benefits of treatments for localized CaP and AUA
recommendations are summarized in Tables 3 and 4. Quality
of life factors such as potency, urinary, or rectal bother should
play an important role in any patient’s treatment decision and a
detailed discussion of these specific issues is beyond the scope
of this paper. A recent publication by Sanda, et al provides
excellent objective data on the potential major quality of life
effects of primary CaP treatment.71
Outcomes for men with low risk disease treated by radiation
or surgery appear to have similar cancer outcomes out to at
least 10–15 years. Perhaps, the younger patient with greater
than ten year life expectancy may benefit from accurate staging
and an undetectable PSA offered by RP. With high risk disease,
adjuvant radiation administered as part of a multimodality
treatment plan following prostatectomy may improve biochemical recurrence and possibly overall survival. Radiation combined

Table 4 Treatment options for localized prostate cancer based on guidelines from the American Urologic Association70
Risk classification

Treatment options

Notes

Low

AS, IR, EBRT, RP, WW

Intermediate

IR, EBRT, RP, WW

High

EBRT, RP, WW

Review patient preferences on QOL issues
High RT dose may decrease PSA recurrence
WW inferior to RP
No data to support superiority
Six month HT + RT
Multimodal approach to treatment
Adjuvant and concurrent HT with RT

Abbreviations: AS, active surveillance; IR, interstitial radiotherapy; EBRT, external beam radiotherapy; RP, radical prostatectomy; WW, watchful waiting.
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with hormonal therapy is currently considered standard of care
for those men with high risk features who opt for external beam
radiation therapy. A patient interested in one single minimally
invasive intervention may seek brachytherapy or cryotherapy.
Finally, a suitable patient for AS may choose this less invasive
route to monitor his CaP. In the end, the treatment of CaP needs
to be individualized for each patient, after weighing in the current information available to each patient’s expectations, overall
health and quality of life.
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